home / stock / nbrv / nbrv quote
Last: | $1.42 |
---|---|
Change Percent: | -2.11% |
Open: | $1.45 |
Close: | $1.42 |
High: | $1.9 |
Low: | $1.35 |
Volume: | 709,759 |
Last Trade Date Time: | 07/31/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.42 | $1.45 | $1.42 | $1.9 | $1.35 | 709,759 | 07-31-2023 |
$1.42 | $1.4385 | $1.42 | $1.47 | $1.39 | 18,861 | 07-28-2023 |
$1.455 | $1.5 | $1.455 | $1.533 | $1.44 | 37,285 | 07-27-2023 |
$1.46 | $1.48 | $1.46 | $1.58 | $1.44 | 18,769 | 07-26-2023 |
$1.47 | $1.48 | $1.47 | $1.59 | $1.44 | 50,605 | 07-25-2023 |
$1.62 | $1.55 | $1.62 | $1.66 | $1.5201 | 22,244 | 07-24-2023 |
$1.62 | $1.63 | $1.62 | $1.63 | $1.62 | 2,915 | 07-21-2023 |
$1.625 | $1.66 | $1.625 | $1.67 | $1.57 | 6,180 | 07-20-2023 |
$1.7173 | $1.67 | $1.7173 | $1.7173 | $1.6503 | 2,245 | 07-19-2023 |
$1.66 | $1.5737 | $1.66 | $1.75 | $1.5737 | 7,971 | 07-18-2023 |
$1.63 | $1.63 | $1.63 | $1.63 | $1.5983 | 3,127 | 07-17-2023 |
$1.5838 | $1.67 | $1.5838 | $1.67 | $1.5838 | 2,265 | 07-14-2023 |
$1.55 | $1.56 | $1.55 | $1.57 | $1.5257 | 7,870 | 07-13-2023 |
$1.52 | $1.5201 | $1.52 | $1.55 | $1.52 | 3,499 | 07-12-2023 |
$1.515 | $1.58 | $1.515 | $1.58 | $1.515 | 9,098 | 07-11-2023 |
$1.5513 | $1.57 | $1.5513 | $1.5988 | $1.55 | 11,661 | 07-10-2023 |
$1.4803 | $1.55 | $1.4803 | $1.55 | $1.4803 | 2,219 | 07-07-2023 |
$1.55 | $1.49 | $1.55 | $1.55 | $1.485 | 2,105 | 07-06-2023 |
$1.5 | $1.54 | $1.5 | $1.54 | $1.4601 | 1,508 | 07-05-2023 |
$1.545 | $1.46 | $1.51 | $1.545 | $1.46 | 6,133 | 07-04-2023 |
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...